ALK-Abelló A/S (AKBLF)
USD 22.05
(0.0%)
USD 22.05
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 439 Million DKK | 2.33% |
| 2022 | 429 Million DKK | 0.0% |
| 2021 | 429 Million DKK | -51.96% |
| 2020 | 893 Million DKK | -5.1% |
| 2019 | 941 Million DKK | 29.79% |
| 2018 | 725 Million DKK | -2.16% |
| 2017 | 741 Million DKK | -2.24% |
| 2016 | 758 Million DKK | 131.1% |
| 2015 | 328 Million DKK | 2.82% |
| 2014 | 319 Million DKK | -0.93% |
| 2013 | 322 Million DKK | -1.53% |
| 2012 | 327 Million DKK | -0.91% |
| 2011 | 330 Million DKK | 791.89% |
| 2010 | 37 Million DKK | -9.76% |
| 2009 | 41 Million DKK | 173.33% |
| 2008 | 15 Million DKK | -76.19% |
| 2007 | 63 Million DKK | -12.5% |
| 2006 | 72 Million DKK | 2.86% |
| 2005 | 70 Million DKK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 451 Million DKK | -2.17% |
| 2024 Q2 | 175 Million DKK | -2.78% |
| 2023 Q3 | 448 Million DKK | 6.41% |
| 2023 Q1 | 431 Million DKK | 0.47% |
| 2023 FY | 439 Million DKK | 2.33% |
| 2023 Q4 | 439 Million DKK | -2.01% |
| 2023 Q2 | 421 Million DKK | -2.32% |
| 2022 Q3 | 445 Million DKK | 1.37% |
| 2022 Q2 | 439 Million DKK | 4.28% |
| 2022 Q1 | 421 Million DKK | -1.86% |
| 2022 FY | 429 Million DKK | 0.0% |
| 2022 Q4 | 429 Million DKK | -3.6% |
| 2021 Q3 | 431 Million DKK | -0.46% |
| 2021 Q4 | 429 Million DKK | -0.46% |
| 2021 FY | 429 Million DKK | -51.96% |
| 2021 Q1 | 893 Million DKK | 0.0% |
| 2021 Q2 | 433 Million DKK | -51.51% |
| 2020 FY | 893 Million DKK | -5.1% |
| 2020 Q1 | 934 Million DKK | -0.74% |
| 2020 Q2 | 921 Million DKK | -1.39% |
| 2020 Q3 | 909 Million DKK | -1.3% |
| 2020 Q4 | 893 Million DKK | -1.76% |
| 2019 Q3 | 908 Million DKK | -0.33% |
| 2019 Q2 | 911 Million DKK | 0.44% |
| 2019 Q4 | 941 Million DKK | 3.63% |
| 2019 Q1 | 907 Million DKK | 25.1% |
| 2019 FY | 941 Million DKK | 29.79% |
| 2018 Q2 | 732 Million DKK | -0.68% |
| 2018 FY | 725 Million DKK | -2.16% |
| 2018 Q3 | 729 Million DKK | -0.41% |
| 2018 Q4 | 725 Million DKK | -0.55% |
| 2018 Q1 | 737 Million DKK | -0.54% |
| 2017 FY | 741 Million DKK | -2.24% |
| 2017 Q3 | 745 Million DKK | -0.53% |
| 2017 Q1 | 754 Million DKK | -0.53% |
| 2017 Q4 | 741 Million DKK | -0.54% |
| 2017 Q2 | 749 Million DKK | -0.66% |
| 2016 Q2 | 319 Million DKK | -1.24% |
| 2016 FY | 758 Million DKK | 131.1% |
| 2016 Q3 | 315 Million DKK | -1.25% |
| 2016 Q4 | 758 Million DKK | 140.63% |
| 2016 Q1 | 323 Million DKK | -1.52% |
| 2015 Q4 | 328 Million DKK | -47.94% |
| 2015 Q1 | 319 Million DKK | 0.0% |
| 2015 Q2 | 634 Million DKK | 98.75% |
| 2015 Q3 | 630 Million DKK | -0.63% |
| 2015 FY | 328 Million DKK | 2.82% |
| 2014 Q1 | 321 Million DKK | -0.31% |
| 2014 Q2 | 321 Million DKK | 0.0% |
| 2014 Q3 | 319 Million DKK | -0.62% |
| 2014 Q4 | 319 Million DKK | 0.0% |
| 2014 FY | 319 Million DKK | -0.93% |
| 2013 Q2 | 325 Million DKK | 0.0% |
| 2013 FY | 322 Million DKK | -1.53% |
| 2013 Q4 | 322 Million DKK | -0.31% |
| 2013 Q3 | 323 Million DKK | -0.62% |
| 2013 Q1 | 325 Million DKK | -0.61% |
| 2012 Q4 | 327 Million DKK | -0.3% |
| 2012 FY | 327 Million DKK | -0.91% |
| 2012 Q1 | 330 Million DKK | 0.0% |
| 2012 Q2 | 329 Million DKK | -0.3% |
| 2012 Q3 | 328 Million DKK | -0.3% |
| 2011 Q4 | 330 Million DKK | 900.0% |
| 2011 Q1 | 36 Million DKK | -2.7% |
| 2011 Q2 | 35 Million DKK | -2.78% |
| 2011 Q3 | 33 Million DKK | -5.71% |
| 2011 FY | 330 Million DKK | 791.89% |
| 2010 Q1 | 40 Million DKK | -2.44% |
| 2010 FY | 37 Million DKK | -9.76% |
| 2010 Q4 | 37 Million DKK | -2.63% |
| 2010 Q3 | 38 Million DKK | -2.56% |
| 2010 Q2 | 39 Million DKK | -2.5% |
| 2009 Q4 | 41 Million DKK | 0.0% |
| 2009 FY | 41 Million DKK | 173.33% |
| 2008 FY | 15 Million DKK | -76.19% |
| 2007 FY | 63 Million DKK | -12.5% |
| 2006 FY | 72 Million DKK | 2.86% |
| 2005 FY | 70 Million DKK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -1999.574% |
| Evofem Biosciences, Inc. | 8000.00 USD | -5487400.0% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -24907.42% |
| Mesoblast Limited | 100.29 Million USD | -337.709% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -748510.211% |
| Genus plc | 228.2 Million USD | -92.375% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -65704.365% |
| ContraFect Corporation | 2.21 Million USD | -19764.253% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -31191.565% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -7989.959% |
| MultiCell Technologies, Inc. | 36.43 USD | -1205050682.322% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -689.398% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -19621.473% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -35638.679% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -164.291% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -23023.908% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -256280.307% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -7964341.219% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -1502.273% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -136235.404% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 96.094% |
| Halberd Corporation | 150 Thousand USD | -292566.667% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -146233.333% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -267248.741% |
| argenx SE | 15.35 Million USD | -2759.19% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -2061.284% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -9851785.099% |
| Genscript Biotech Corporation | 287.12 Million USD | -52.893% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -347479.611% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -191359.761% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -79057.576% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -1735146.452% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -5212.197% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -165164.367% |
| ONE Bio Corp. | 592.19 Thousand USD | -74030.612% |
| Reve Technologies, Inc. | 1064.00 USD | -41259298.496% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -293321.739% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -293321.739% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -191026.339% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -311247.518% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -548650.0% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -5513.839% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -118854.394% |
| International Stem Cell Corporation | 445 Thousand USD | -98551.685% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -5286.503% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -95961.269% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -37712.231% |
| PureTech Health plc | 18.25 Million USD | -2305.479% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -292566.667% |
| IXICO plc | 275 Thousand USD | -159536.364% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -3608.083% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -1568.631% |
| CSL Limited | 11.23 Billion USD | 96.094% |
| Cellectis S.A. | 36.21 Million USD | -1112.334% |